JPH07501000A - 歩行可能なクリアランス機能モニター - Google Patents
歩行可能なクリアランス機能モニターInfo
- Publication number
- JPH07501000A JPH07501000A JP5509510A JP50951093A JPH07501000A JP H07501000 A JPH07501000 A JP H07501000A JP 5509510 A JP5509510 A JP 5509510A JP 50951093 A JP50951093 A JP 50951093A JP H07501000 A JPH07501000 A JP H07501000A
- Authority
- JP
- Japan
- Prior art keywords
- detector
- radiation
- substance
- detectable substance
- detectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims description 102
- 230000005855 radiation Effects 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 35
- 238000012544 monitoring process Methods 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 24
- 230000004888 barrier function Effects 0.000 claims description 23
- 238000005259 measurement Methods 0.000 claims description 19
- 210000001723 extracellular space Anatomy 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 210000003722 extracellular fluid Anatomy 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 2
- 229910004613 CdTe Inorganic materials 0.000 claims 1
- 230000006870 function Effects 0.000 description 29
- 230000003907 kidney function Effects 0.000 description 27
- 210000003734 kidney Anatomy 0.000 description 20
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 210000002700 urine Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 230000024924 glomerular filtration Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical group C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002991 molded plastic Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000007371 visceral function Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229910004606 CdTc Inorganic materials 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010057410 Hippus Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012905 input function Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940083604 sodium iothalamate Drugs 0.000 description 1
- WCIMWHNSWLLELS-ZMWPDAOESA-M sodium;3-acetamido-2,6-bis(iodanyl)-4-iodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C([125I])C(C([O-])=O)=C1[125I] WCIMWHNSWLLELS-ZMWPDAOESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
- G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
- G01T1/16—Measuring radiation intensity
- G01T1/161—Applications in the field of nuclear medicine, e.g. in vivo counting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/16—Details of sensor housings or probes; Details of structural supports for sensors
- A61B2562/17—Comprising radiolucent components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/507—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for determination of haemodynamic parameters, e.g. perfusion CT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- High Energy & Nuclear Physics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Telephone Function (AREA)
- Emergency Alarm Devices (AREA)
- Nuclear Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Fire-Detection Mechanisms (AREA)
Abstract
Description
Claims (15)
- 1.被検体の身体の一部から検出可能物質の消耗を測定する方法において、前記 検出可能物質が定義された組織体積内にある時、実質的にかかる検出可能物質に のみ応答するように該検出可能物質に応答し得る検出器を配置し、前記検出可能 物質に対する前記検出器の応答を測定すること、を含む方法。
- 2.被検体におけるクリアランス機能を測定する方法において、前記検出可能物 質が定義された組織体積内にある時、実質的にかかる検出可能物質にのみ応答す るように該検出可能物質に応答し得る検出器を配置し、前記検出可能物質に対す る前記検出器の応答を測定することを含み、これにより、前記検出可能物質の量 の変化が前記クリアランス機能を表わすようにする 方法。
- 3.前記検出可能物質からの放射を検出することにより該物質を検出可能である 請求の範囲第1項または第2項に記載の方法。
- 4.全体的に検出可能物質が放射性を有し、前記検出器が放射線検出器を含む請 求の範囲第3項記載の方法。
- 5.前記検出可能物質が蛍光物質であり、前記検出器が光検出器を含む請求の範 囲第3項記載の方法。
- 6.前記標識物質が標識を付される請求の範囲第1項または第2項に記載の方法 。
- 7.前記標識を付した物質が放射性標識を付され、前記検出器が放射線検出器を 含む請求の範囲第5項記載の方法。
- 8.前記放射線検出器がシンチレータを含む請求の範囲第4項または第7項に記 載の方法。
- 9.前記放射線検出器がNaI放射線検出器を含む請求の範囲第8項記載の方法 。
- 10.前記放射線検出器がCdTe放射線検出器を含む請求の範囲第4項または 第7項に記載の方法。
- 11.前記検出可能物質が定義された組織体積内にある時、実質的にかかる検出 可能物質にのみ応答するように、前記検出器を配置する前記ステップが、前記検 出器を前記放射線に対して実質的に不透過であるバリア内に包囲することを含み 、該バリアが、前記放射線が前記検出器の感応部分に通過する開口を有する請求 の範囲第3項記載の方法。
- 12.前記検出可能物質が定義された組織体積内にある時、実質的にかかる検出 可能物質にのみ応答するように、前記検出器を配置する前記ステップが、前記検 出器を前記放射線に対して実質的に不透過であるバリア内に包囲することを含み 、前記検出可能物質が前記バリア内にある時、かかる検出可能物質のからの前記 放射線が前記検出器の感応部分に通過し得るように前記検出器を配置する請求の 範囲第3項記載の方法。
- 13.前記検出可能物質が被検体内に注入される請求の範囲第1項または第2項 に記載の方法。
- 14.被検体からの検出可能物質の消耗を監視する装置において、前記検出可能 物質からの放射線に応答し得る検出器と、前記放射線に対して実質的に不透過で あり、前記被検体の身体の一部を包囲するためのバリアとを備え、 前記検出器および前記バリアが、前記検出可能物質が前記バリア内にある時、か かる検出可能物質からの放射線が前記検出器の感応部分に通過し得るように用い られる 装置。
- 15.被検体におけるクリアランス機能を決定して表示する方法において、前記 被検体における細胞外空間における検出可能物質の平衡状態の確立を許容するに 充分な時間を与え、 前記被検体における定義された組織体積内の細胞外液中の検出可能物質の最初の 測定を得ること、 前記定義された組織体積中の前記細胞外液における検出可能物質の2回目の測定 を得ること、 時間間隔にわたり前記測定の勾配を決定すること、を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/793,781 US5301673A (en) | 1991-11-18 | 1991-11-18 | Ambulatory clearance function monitor |
US793,781 | 1991-11-18 | ||
PCT/US1992/009967 WO1993010470A1 (en) | 1991-11-18 | 1992-11-18 | Ambulatory clearance function monitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07501000A true JPH07501000A (ja) | 1995-02-02 |
JP3694315B2 JP3694315B2 (ja) | 2005-09-14 |
Family
ID=25160778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50951093A Expired - Lifetime JP3694315B2 (ja) | 1991-11-18 | 1992-11-18 | 歩行可能なクリアランス機能モニター |
Country Status (8)
Country | Link |
---|---|
US (2) | US5301673A (ja) |
EP (1) | EP0613562B1 (ja) |
JP (1) | JP3694315B2 (ja) |
AT (1) | ATE147865T1 (ja) |
AU (1) | AU3142293A (ja) |
CA (1) | CA2123795A1 (ja) |
DE (1) | DE69216850D1 (ja) |
WO (1) | WO1993010470A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525914A (ja) * | 2000-03-06 | 2003-09-02 | マリンクロッド・インコーポレイテッド | 生理的機能の同時多重モデル測定 |
JPWO2006038386A1 (ja) * | 2004-10-04 | 2008-05-15 | 国立大学法人名古屋大学 | 放射性同位元素検出用プローブ、および放射性同位元素検出方法 |
JP2010509605A (ja) * | 2006-11-14 | 2010-03-25 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 被検体内の放射性医薬品の分布を決定するシステム |
JP2020041930A (ja) * | 2018-09-12 | 2020-03-19 | 独立行政法人国立高等専門学校機構 | 放射能測定装置、放射能測定方法、放射能情報処理サーバおよび放射能情報処理システム |
JP2020516680A (ja) * | 2017-10-27 | 2020-06-11 | メディビーコン,インク. | 腎機能測定のための組成物及びシステム |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5301673A (en) * | 1991-11-18 | 1994-04-12 | Massachusetts General Hospital | Ambulatory clearance function monitor |
US5477860A (en) * | 1992-11-05 | 1995-12-26 | Synectics Medical, Inc. | Catheter for measuring respiration and respiratory effort |
US5810741A (en) * | 1992-11-05 | 1998-09-22 | Synectics Medical Ab | Method of measuring respiration and respiratory effort using plural catheters |
US5438985A (en) * | 1993-01-25 | 1995-08-08 | Synectics Medical, Incorporated | Ambulatory recording of the presence and activity of substances in gastro-intestinal compartments |
US5657759A (en) * | 1993-05-13 | 1997-08-19 | Synectics Medical, Incorporated | Measurement of gastric emptying and gastrointestinal output |
US5551425A (en) * | 1993-05-13 | 1996-09-03 | Synectics Medical, Inc. | Potential difference and perfusion pressure catheter |
US5507289A (en) * | 1993-09-16 | 1996-04-16 | Synectics Medical, Inc. | System and method to diagnose bacterial growth |
US5477854A (en) * | 1993-09-16 | 1995-12-26 | Synectics Medical, Inc. | System and method to monitor gastrointestinal Helicobacter pylori infection |
US5479935A (en) * | 1993-10-21 | 1996-01-02 | Synectics Medical, Inc. | Ambulatory reflux monitoring system |
US5833625A (en) * | 1993-10-21 | 1998-11-10 | Synectics Medical Ab | Ambulatory reflux monitoring system |
US5722396A (en) * | 1996-08-13 | 1998-03-03 | St. Luke's-Roosevelt Hospital Center | Method for estimating creatinine clearance using measurements of body cell mass |
US6228344B1 (en) | 1997-03-13 | 2001-05-08 | Mallinckrodt Inc. | Method of measuring physiological function |
US5928625A (en) * | 1997-03-13 | 1999-07-27 | Mallinckrodt Inc. | Method of measuring physiological function |
WO2000059376A1 (en) * | 1999-04-07 | 2000-10-12 | Endonetics, Inc. | Implantable monitoring probe |
US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
US6440389B1 (en) | 2000-07-19 | 2002-08-27 | The General Hospital Corporation | Fluorescent agents for real-time measurement of organ function |
US7048907B2 (en) * | 2001-02-05 | 2006-05-23 | Biophysics Assay Laboratory, Inc. | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products |
US20030215391A1 (en) * | 2001-07-19 | 2003-11-20 | Carlos Rabito | Fluorescent agents for real-time measurement of organ function |
DE10225932B4 (de) * | 2002-06-11 | 2007-01-11 | Deutsches Krebsforschungszentrum (Dkfz) | Bildgebendes Verfahren und Vorrichtung zu dessen Durchführung |
JP4468878B2 (ja) * | 2005-10-07 | 2010-05-26 | テルモ株式会社 | 血圧測定用カフおよび血圧測定装置 |
US9675285B2 (en) * | 2006-10-16 | 2017-06-13 | Given Imaging Ltd. | Delivery device for implantable monitor |
US8219171B2 (en) * | 2010-03-16 | 2012-07-10 | Given Imaging Ltd. | Delivery device for implantable monitor |
US9002438B2 (en) * | 2012-05-30 | 2015-04-07 | Lucerno Dynamics | System for the detection of gamma radiation from a radioactive analyte |
US9939533B2 (en) | 2012-05-30 | 2018-04-10 | Lucerno Dynamics, Llc | System and method for the detection of gamma radiation from a radioactive analyte |
FR3001299B1 (fr) * | 2013-01-23 | 2016-07-22 | Ag Medical | Dispositif de radiologie |
CA2904334C (en) * | 2013-03-15 | 2024-02-20 | Ajay Verma | Assessment of labeled probes in a subject |
WO2015121843A1 (en) * | 2014-02-17 | 2015-08-20 | Winmedical S.R.L. | A device for measuring a plurality of parameters in patient subject to a treatment with radiopharmaceuticals |
US9457754B1 (en) | 2015-07-13 | 2016-10-04 | State Farm Mutual Automobile Insurance Company | Method and system for identifying vehicle collisions using sensor data |
CA2999873A1 (en) | 2015-09-25 | 2017-03-30 | Biogen Ma Inc. | Wearable medical detector |
USD795890S1 (en) | 2015-10-16 | 2017-08-29 | Biogen Ma Inc. | Display screen with a graphical user interface |
WO2018098221A1 (en) | 2016-11-22 | 2018-05-31 | Biogen Ma Inc. | Medical diagnostic and treatment systems and their methods of use |
CN109490938B (zh) * | 2018-12-21 | 2021-01-01 | 苏州瑞派宁科技有限公司 | 一种辐射监测装置 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3827427A (en) * | 1973-01-08 | 1974-08-06 | Atomic Energy Commission | Apparatus for measuring radioactivity in the human eye |
US4092980A (en) * | 1976-01-12 | 1978-06-06 | G. D. Searle & Co. | Fibrinogen monitor |
DE2641039C3 (de) * | 1976-09-11 | 1979-07-19 | Peter Dipl.-Ing. Dr.Med. 3000 Hannover Pretschner | Vorrichtung zur Bestimmung der Strahlung einer radioaktiv markierten, in den menschlichen Körper eingebrachten Substanz mit einem Detektor und einer einen digitalen Speicher enthaltenden Auswerteschaltung |
US4281645A (en) * | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4243884A (en) * | 1978-11-09 | 1981-01-06 | Actus, Inc. | Probe assembly |
US4329986A (en) * | 1979-06-14 | 1982-05-18 | Biomedics, Inc. | Treatment of an extracorporeal stream of blood with a dialyzable chemotherapeutic and a fluorescable tracer |
EP0059032A1 (en) * | 1981-02-03 | 1982-09-01 | Virgil B. Elings | Measurement of dye concentration in the bloodstream |
DE3245778A1 (de) * | 1982-12-10 | 1984-06-14 | Rudolf Dr. 7750 Konstanz Junges | Clearance-verfahren und vorrichtung zu seiner durchfuehrung |
US4682604A (en) * | 1985-02-25 | 1987-07-28 | The Regents Of The University Of California | Coincidence counting emission tomographic probe: method and apparatus |
EP0197786A1 (en) * | 1985-04-10 | 1986-10-15 | Lahiri, Avijit | Improvements relating to cardiac and the like monitoring |
US4893013A (en) * | 1987-03-17 | 1990-01-09 | Neoprobe Corporation | Detector and localizer for low energy radiation emissions |
US4798955A (en) * | 1987-09-23 | 1989-01-17 | Futrex, Inc. | Measurement locator and light shield for use in interactance testing of body composition and method for use thereof |
CA1328018C (en) * | 1987-11-13 | 1994-03-22 | Masahiko Kanda | Liver function testing apparatus |
DE3802996A1 (de) * | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
JPH0657216B2 (ja) * | 1988-09-14 | 1994-08-03 | 住友電気工業株式会社 | 肝機能検査装置 |
US4889991A (en) * | 1988-09-23 | 1989-12-26 | Neoprobe Corporation | Gamma radiation detector with enhanced signal treatment |
US4992255A (en) * | 1988-12-19 | 1991-02-12 | Pardridge William M | Capillary depletion method for quantifying transcytosis through the blood-brain barrier |
US5233997A (en) * | 1991-04-04 | 1993-08-10 | Baylor College Of Medicine | Non-invasive measure of intestinal transit time and uses thereof |
US5301673A (en) * | 1991-11-18 | 1994-04-12 | Massachusetts General Hospital | Ambulatory clearance function monitor |
US5335660A (en) * | 1993-08-12 | 1994-08-09 | General Electric Company | Magnetic resonance method of measuring kidney filtration rates |
-
1991
- 1991-11-18 US US07/793,781 patent/US5301673A/en not_active Expired - Lifetime
-
1992
- 1992-11-18 AU AU31422/93A patent/AU3142293A/en not_active Abandoned
- 1992-11-18 EP EP92925324A patent/EP0613562B1/en not_active Expired - Lifetime
- 1992-11-18 WO PCT/US1992/009967 patent/WO1993010470A1/en active IP Right Grant
- 1992-11-18 JP JP50951093A patent/JP3694315B2/ja not_active Expired - Lifetime
- 1992-11-18 CA CA002123795A patent/CA2123795A1/en not_active Abandoned
- 1992-11-18 AT AT92925324T patent/ATE147865T1/de not_active IP Right Cessation
- 1992-11-18 DE DE69216850T patent/DE69216850D1/de not_active Expired - Lifetime
-
1994
- 1994-04-11 US US08/225,646 patent/US5647363A/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525914A (ja) * | 2000-03-06 | 2003-09-02 | マリンクロッド・インコーポレイテッド | 生理的機能の同時多重モデル測定 |
JPWO2006038386A1 (ja) * | 2004-10-04 | 2008-05-15 | 国立大学法人名古屋大学 | 放射性同位元素検出用プローブ、および放射性同位元素検出方法 |
JP2010509605A (ja) * | 2006-11-14 | 2010-03-25 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 被検体内の放射性医薬品の分布を決定するシステム |
JP2020516680A (ja) * | 2017-10-27 | 2020-06-11 | メディビーコン,インク. | 腎機能測定のための組成物及びシステム |
JP2023009041A (ja) * | 2017-10-27 | 2023-01-19 | メディビーコン,インク. | 腎機能測定のための組成物及びシステム |
JP2020041930A (ja) * | 2018-09-12 | 2020-03-19 | 独立行政法人国立高等専門学校機構 | 放射能測定装置、放射能測定方法、放射能情報処理サーバおよび放射能情報処理システム |
Also Published As
Publication number | Publication date |
---|---|
DE69216850D1 (de) | 1997-02-27 |
EP0613562B1 (en) | 1997-01-15 |
US5647363A (en) | 1997-07-15 |
WO1993010470A1 (en) | 1993-05-27 |
ATE147865T1 (de) | 1997-02-15 |
AU3142293A (en) | 1993-06-15 |
US5301673A (en) | 1994-04-12 |
JP3694315B2 (ja) | 2005-09-14 |
CA2123795A1 (en) | 1993-05-27 |
EP0613562A1 (en) | 1994-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3694315B2 (ja) | 歩行可能なクリアランス機能モニター | |
Kuhl et al. | Local cerebral blood volume determined by three-dimensional reconstruction of radionuclide scan data. | |
US5287273A (en) | Functional organ images | |
US6445945B1 (en) | Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs using tracer injection | |
Wagner Jr et al. | Monitoring ventricular function at rest and during exercise with a nonimaging nuclear detector | |
Rabito et al. | Noninvasive, real-time monitoring of renal function: the ambulatory renal monitor | |
JP4656008B2 (ja) | 核医学診断装置 | |
Rabito et al. | Noninvasive, real-time monitoring of renal function during critical care. | |
Jona et al. | Simplified radioisotope technique for assessing gastroesophageal reflux in children | |
Strandell et al. | The effect in humans of exercise on relationship between simultaneously measured 133Xe and 24Na clearances | |
Hoffer et al. | A miniature cadmium telluride detector module for continuous monitoring of left-ventricular function. | |
Farmelant et al. | The renogram: physiologic basis and current clinical use | |
Ellis et al. | In vivo monitoring of skeletal aluminum burden in patients with renal failure | |
Lerch et al. | Kinetics of positron emitters in vivo characterized with a beta probe | |
WO2003051193A1 (en) | Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs | |
Merriman et al. | Serial cardiac output determinations in man | |
Wathen et al. | A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics | |
Budinger et al. | Medical criteria for the design of a dynamic positron tomograph for heart studies | |
SU1250256A1 (ru) | Способ определени очистительной функции выделительных органов | |
Schelbert et al. | Physiologic tomography: a new means for the non-invasive measurement of myocardial metabolism, blood flow and function | |
Shiomi et al. | Measurement of hepatic blood flow by use of per-rectal portal scintigraphy with 133Xe | |
Groshar et al. | Detection of Permanent Damage in Kidneys with Vesicoureteral Reflux by Quantitative Single Photon Emission Computerized Tomography (Spect) Uptake of sup 99m Technetium Labeled Dimercaptosuccinic Acid | |
Bojsen et al. | Biotelemetry based on CdTe-detectors | |
RU2553186C1 (ru) | Способ определения всасывательной функции тонкой кишки | |
Lecomte et al. | Cardiac PET imaging of blood flow, metabolism and function in normal and infarcted rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050624 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090701 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100701 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110701 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120701 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120701 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130701 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130701 Year of fee payment: 8 |